. . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . "klinisch onderzoek"@nl . . . . . . . . . . "2013-06-01T00:00:00Z"^^ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "clinical trial"@en . . . . . . . "BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab"@en . . . . . . . . "NCT00625898" . "A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab"@en . . . . . . . . . . . . . . . . "18"^^ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "2008-04-01T00:00:00Z"^^ . . . . . . . . . . . . . . . . . . . "ensayu cl\u00EDnicu"@ast . . . . . . . . . . . "3509"^^ . . . . . . . . . . . . . . . . . . . . . . . . . . . . "BETH"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab"@en . . . . . . . . . . . . . . . . "BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab"@en . . . . . . . . . . . . . . . . . . . .